Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 290

1.

Clinical and genetic characteristics of late-onset Huntington's disease.

Oosterloo M, Bijlsma EK, van Kuijk SM, Minkels F, de Die-Smulders CE; REGISTRY Investigators of the European Huntington's Disease Network; Registry Steering committee; Language coordinators; EHDN's associate site in Singapore.

Parkinsonism Relat Disord. 2018 Nov 29. pii: S1353-8020(18)30490-5. doi: 10.1016/j.parkreldis.2018.11.009. [Epub ahead of print]

PMID:
30528461
2.

Reduced Cancer Incidence in Huntington's Disease: Analysis in the Registry Study.

McNulty P, Pilcher R, Ramesh R, Necuiniate R, Hughes A, Farewell D, Holmans P, Jones L; REGISTRY Investigators of the European Huntington's Disease Network .

J Huntingtons Dis. 2018;7(3):209-222. doi: 10.3233/JHD-170263.

PMID:
30103338
3.

The influence of motor ability rehabilitation on temporal-spatial parameters of gait in Huntington's disease patients on the basis of a three-dimensional motion analysis system: An experimental trial.

Mirek E, Filip M, Chwała W, Szymura J, Pasiut S, Banaszkiewicz K, Bar MR, Szczudlik A.

Neurol Neurochir Pol. 2018 Sep - Oct;52(5):575-580. doi: 10.1016/j.pjnns.2018.02.001. Epub 2018 Feb 12.

PMID:
29475565
4.

Virtual Reality for Upper Limb Rehabilitation in Subacute and Chronic Stroke: A Randomized Controlled Trial.

Kiper P, Szczudlik A, Agostini M, Opara J, Nowobilski R, Ventura L, Tonin P, Turolla A.

Arch Phys Med Rehabil. 2018 May;99(5):834-842.e4. doi: 10.1016/j.apmr.2018.01.023. Epub 2018 Feb 14.

PMID:
29453980
5.

The relation between plasma α-synuclein level and clinical symptoms or signs of Parkinson's disease.

Malec-Litwinowicz M, Plewka A, Plewka D, Bogunia E, Morek M, Szczudlik A, Szubiga M, Rudzińska-Bar M.

Neurol Neurochir Pol. 2018 Mar;52(2):243-251. doi: 10.1016/j.pjnns.2017.11.009. Epub 2017 Nov 21.

PMID:
29342421
6.

Alpha-2-antiplasmin Arg407Lys polymorphism and cryptogenic ischemic cerebrovascular events: Association with neurological deficit.

Wzorek J, Karpiński M, Wypasek E, Michalski M, Szczudlik A, Malinowski KP, Undas A.

Neurol Neurochir Pol. 2018 May - Jun;52(3):352-358. doi: 10.1016/j.pjnns.2017.12.009. Epub 2017 Dec 26.

PMID:
29306602
7.

Three-Dimensional Trunk and Lower Limbs Characteristics during Gait in Patients with Huntington's Disease.

Mirek E, Filip M, Chwała W, Banaszkiewicz K, Rudzinska-Bar M, Szymura J, Pasiut S, Szczudlik A.

Front Neurosci. 2017 Oct 12;11:566. doi: 10.3389/fnins.2017.00566. eCollection 2017.

8.

Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study.

Skrobot OA, Black SE, Chen C, DeCarli C, Erkinjuntti T, Ford GA, Kalaria RN, O'Brien J, Pantoni L, Pasquier F, Roman GC, Wallin A, Sachdev P, Skoog I; VICCCS group, Ben-Shlomo Y, Passmore AP, Love S, Kehoe PG.

Alzheimers Dement. 2018 Mar;14(3):280-292. doi: 10.1016/j.jalz.2017.09.007. Epub 2017 Oct 19.

PMID:
29055812
9.

Eye movements in essential tremor patients with parkinsonian and cerebellar signs.

Wójcik-Pędziwiatr M, Mirek E, Rudzińska-Bar M, Szczudlik A.

Neurol Neurochir Pol. 2017 Jul - Aug;51(4):299-303. doi: 10.1016/j.pjnns.2017.05.001. Epub 2017 May 17.

PMID:
28673510
10.

Opposite effects of l-dopa and DBS-STN on saccadic eye movements in advanced Parkinson's disease.

Dec-Ćwiek M, Tutaj M, Gracies JM, Volkmann J, Rudzińska M, Słowik A, Szczudlik A.

Neurol Neurochir Pol. 2017 Sep - Oct;51(5):354-360. doi: 10.1016/j.pjnns.2017.06.002. Epub 2017 Jun 24.

PMID:
28669542
11.

Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.

Moss DJH, Pardiñas AF, Langbehn D, Lo K, Leavitt BR, Roos R, Durr A, Mead S; TRACK-HD investigators; REGISTRY investigators, Holmans P, Jones L, Tabrizi SJ.

Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20. Erratum in: Lancet Neurol. 2017 Sep;16(9):683.

PMID:
28642124
12.

Sodium intake and multiple sclerosis activity and progression in BENEFIT.

Fitzgerald KC, Munger KL, Hartung HP, Freedman MS, Montalbán X, Edan G, Wicklein EM, Radue EW, Kappos L, Pohl C, Ascherio A; BENEFIT Study Group.

Ann Neurol. 2017 Jul;82(1):20-29. doi: 10.1002/ana.24965.

13.

Eye movement abnormalities in essential tremor.

Wójcik-Pędziwiatr M, Plinta K, Krzak-Kubica A, Zajdel K, Falkiewicz M, Dylak J, Ober J, Szczudlik A, Rudzińska M.

J Hum Kinet. 2016 Sep 10;52:53-64. doi: 10.1515/hukin-2015-0193. eCollection 2016 Sep 1.

14.

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators.

N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21.

15.

The Vascular Impairment of Cognition Classification Consensus Study.

Skrobot OA, O'Brien J, Black S, Chen C, DeCarli C, Erkinjuntti T, Ford GA, Kalaria RN, Pantoni L, Pasquier F, Roman GC, Wallin A, Sachdev P, Skoog I; VICCCS group, Ben-Shlomo Y, Passmore AP, Love S, Kehoe PG.

Alzheimers Dement. 2017 Jun;13(6):624-633. doi: 10.1016/j.jalz.2016.10.007. Epub 2016 Dec 10.

PMID:
27960092
16.

Suicidality and its determinants among Polish patients with epilepsy.

Bosak M, Turaj W, Dudek D, Siwek M, Szczudlik A.

Neurol Neurochir Pol. 2016 Nov - Dec;50(6):432-438. doi: 10.1016/j.pjnns.2016.07.009. Epub 2016 Jul 28.

PMID:
27550747
17.

Computational models and motor learning paradigms: Could they provide insights for neuroplasticity after stroke? An overview.

Kiper P, Szczudlik A, Venneri A, Stozek J, Luque-Moreno C, Opara J, Baba A, Agostini M, Turolla A.

J Neurol Sci. 2016 Oct 15;369:141-148. doi: 10.1016/j.jns.2016.08.019. Epub 2016 Aug 11. Review.

18.

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group.

Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10.

19.

Clinical manifestations of intermediate allele carriers in Huntington disease.

Cubo E, Ramos-Arroyo MA, Martinez-Horta S, Martínez-Descalls A, Calvo S, Gil-Polo C; European HD Network.

Neurology. 2016 Aug 9;87(6):571-8. doi: 10.1212/WNL.0000000000002944. Epub 2016 Jul 8.

PMID:
27402890
20.

Is hypertension a risk factor of hemifacial spasm?

Rudzińska M, Wójcik-Pędziwiatr M, Malec-Litwinowicz M, Grabska N, Hartel M, Flak M, Szczudlik A.

Neurol Neurochir Pol. 2016;50(2):69-74. doi: 10.1016/j.pjnns.2015.11.002. Epub 2015 Nov 25.

PMID:
26969561

Supplemental Content

Loading ...
Support Center